Menu
Back to Archived Journals » Oncolytic Virotherapy
Oncolytic Virotherapy ceased publishing in September 2023. All articles that have been published in Oncolytic Virotherapy will continue to be available on the Dove Press site, and will be securely archived with CLOCKSS.
Oncolytic Virotherapy
ISSN: 2253-1572
- View all (70)
- Volume 10, 2021 (1)
- Volume 9, 2020 (2)
- Volume 8, 2019 (6)
- Volume 7, 2018 (11)
- Volume 6, 2017 (6)
- Volume 5, 2016 (10)
- Volume 4, 2015 (20)
- Volume 3, 2014 (8)
- Volume 2, 2013 (5)
- Volume 1, 2012 (1)
Journal Articles:
- 70 records -
The Current State of Oncolytic Herpes Simplex Virus for Glioblastoma Treatment
Nguyen HM, Saha D
Oncolytic Virotherapy 2021, 10:1-27
Published Date: 24 February 2021
Treatment of an Alveolar Rhabdomyosarcoma Allograft with Recombinant Myxoma Virus and Oclacitinib
Ashton LV, Graham B, Afzali MF, Gustafson D, MacNeill AL
Oncolytic Virotherapy 2020, 9:17-29
Published Date: 26 May 2020
Virus–Receptor Interactions and Virus Neutralization: Insights for Oncolytic Virus Development
Jayawardena N, Poirier JT, Burga LN, Bostina M
Oncolytic Virotherapy 2020, 9:1-15
Published Date: 6 March 2020
Impact of Induced Syncytia Formation on the Oncolytic Potential of Myxoma Virus
Burton C, Bartee MY, Bartee E
Oncolytic Virotherapy 2019, 8:57-69
Published Date: 9 December 2019
Virus–Receptor Interactions: Structural Insights For Oncolytic Virus Development
Jayawardena N, Burga LN, Poirier JT, Bostina M
Oncolytic Virotherapy 2019, 8:39-56
Published Date: 29 October 2019
Preclinical And Clinical Development Of Oncolytic Adenovirus For The Treatment Of Malignant Glioma
Kiyokawa J, Wakimoto H
Oncolytic Virotherapy 2019, 8:27-37
Published Date: 24 October 2019
Directed evolution as a tool for the selection of oncolytic RNA viruses with desired phenotypes
Zainutdinov SS, Kochneva GV, Netesov SV, Chumakov PM, Matveeva OV
Oncolytic Virotherapy 2019, 8:9-26
Published Date: 12 July 2019
A cautionary note on the selectivity of oncolytic poxviruses
Tang B, Guo ZS, Bartlett DL, Liu J, McFadden G, Shisler JL, Roy EJ
Oncolytic Virotherapy 2019, 8:3-8
Published Date: 11 February 2019
Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma [Corrigendum]
Babiker HM, Riaz IR, Husnain M, Borad MJ
Oncolytic Virotherapy 2019, 8:1-2
Published Date: 4 January 2019
Development and applications of oncolytic Maraba virus vaccines
Pol JG, Atherton MJ, Bridle BW, Stephenson KB, Le Boeuf F, Hummel JL, Martin CG, Pomoransky J, Breitbach CJ, Diallo JS, Stojdl DF, Bell JC, Wan Y, Lichty BD
Oncolytic Virotherapy 2018, 7:117-128
Published Date: 26 November 2018
Oncolytic myxoma virus synergizes with standard of care for treatment of glioblastoma multiforme
Burton C, Das A, McDonald D, Vandergrift III WA, Patel SJ, Cachia D, Bartee E
Oncolytic Virotherapy 2018, 7:107-116
Published Date: 19 November 2018
Oral poliovirus vaccine-induced programmed cell death involves both intrinsic and extrinsic pathways in human colorectal cancer cells
Zhand S, Hosseini SM, Tabarraei A, Saeidi M, Saghaeian Jazi M, Kalani MR, Moradi A
Oncolytic Virotherapy 2018, 7:95-105
Published Date: 30 October 2018
Three-dimensional tumor cell cultures employed in virotherapy research
Kloker LD, Yurttas C, Lauer UM
Oncolytic Virotherapy 2018, 7:79-93
Published Date: 5 September 2018
Oncolytic virus and PD-1/PD-L1 blockade combination therapy
Chen CY, Hutzen B, Wedekind MF, Cripe TP
Oncolytic Virotherapy 2018, 7:65-77
Published Date: 31 July 2018
Current understanding of reovirus oncolysis mechanisms
Phillips MB, Stuart JD, Rodríguez Stewart RM, Berry JTL, Mainou BA, Boehme KW
Oncolytic Virotherapy 2018, 7:53-63
Published Date: 14 June 2018
Oncolytic adenovirus Ad657 for systemic virotherapy against prostate cancer
Nguyen TV, Crosby CM, Heller GJ, Mendel ZI, Barry ME, Barry MA
Oncolytic Virotherapy 2018, 7:43-51
Published Date: 3 May 2018
Proof-of-principle that a decoy virus protects oncolytic measles virus against neutralizing antibodies
Xu C, Goß AV, Dorneburg C, Debatin KM, Wei J, Beltinger C
Oncolytic Virotherapy 2018, 7:37-41
Published Date: 30 April 2018
The importance of imaging strategies for pre-clinical and clinical in vivo distribution of oncolytic viruses
Pelin A, Wang J, Bell J, Le Boeuf F
Oncolytic Virotherapy 2018, 7:25-35
Published Date: 28 March 2018
Oncolytic virotherapy in upper gastrointestinal tract cancers
Yokoda R, Nagalo BM, Arora M, Egan JB, Bogenberger JM, DeLeon TT, Zhou Y, Ahn DH, Borad MJ
Oncolytic Virotherapy 2018, 7:13-24
Published Date: 23 March 2018
Potential of oncolytic viruses in the treatment of multiple myeloma
Bartee E
Oncolytic Virotherapy 2018, 7:1-12
Published Date: 23 February 2018
Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect
Yokoda R, Nagalo BM, Vernon B, Oklu R, Albadawi H, DeLeon TT, Zhou Y, Egan JB, Duda DG, Borad MJ
Oncolytic Virotherapy 2017, 6:39-49
Published Date: 8 November 2017
Curative effect of HF10 on liver and peritoneal metastasis mediated by host antitumor immunity
Hotta Y, Kasuya H, Bustos I, Naoe Y, Ichinose T, Tanaka M, Kodera Y
Oncolytic Virotherapy 2017, 6:31-38
Published Date: 13 March 2017
Proinflammatory response induced by Newcastle disease virus in tumor and normal cells
Ginting TE, Suryatenggara J, Christian S, Mathew G
Oncolytic Virotherapy 2017, 6:21-30
Published Date: 3 March 2017
Editorial announcing PubMed indexing of Oncolytic Virotherapy
Farassati F
Oncolytic Virotherapy 2017, 6:19-20
Published Date: 15 February 2017
Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma
Babiker HM, Riaz IB, Husnain M, Borad MJ
Oncolytic Virotherapy 2017, 6:11-18
Published Date: 9 February 2017
Novel oncolytic viral therapies in patients with thoracic malignancies
Ahmad Z, Kratzke RA
Oncolytic Virotherapy 2017, 6:1-9
Published Date: 21 December 2016
CXCL12 retargeting of an adenovirus vector to cancer cells using a bispecific adapter
Bhatia S, O’Bryan SM, Rivera AA, Curiel DT, Mathis JM
Oncolytic Virotherapy 2016, 5:99-113
Published Date: 11 November 2016
Spotlight on talimogene laherparepvec for the treatment of melanoma lesions in the skin and lymph nodes
Orloff M
Oncolytic Virotherapy 2016, 5:91-98
Published Date: 4 October 2016
Oncolytic Seneca Valley Virus: past perspectives and future directions
Burke MJ
Oncolytic Virotherapy 2016, 5:81-89
Published Date: 6 September 2016
Oncolytic virotherapy for pediatric malignancies: future prospects
Waters AM, Friedman GK, Ring EK, Beierle EA
Oncolytic Virotherapy 2016, 5:73-80
Published Date: 11 August 2016
Myxoma virus therapy of human embryonal rhabdomyosarcoma in a nude mouse model
Kinn VG, Hilgenberg VA, MacNeill AL
Oncolytic Virotherapy 2016, 5:59-71
Published Date: 8 August 2016
Oncolytic adenovirus-mediated therapy for prostate cancer
Sweeney K, Halldén G
Oncolytic Virotherapy 2016, 5:45-57
Published Date: 14 July 2016
Thyroid malignant neoplasm-associated biomarkers as targets for oncolytic virotherapy
Guan M, Ma Y, Shah SR, Romano G
Oncolytic Virotherapy 2016, 5:35-43
Published Date: 21 June 2016
Newcastle disease virus, rituximab, and doxorubicin combination as anti-hematological malignancy therapy
Al-Shammari AM, Rameez H, Al-Taee MF
Oncolytic Virotherapy 2016, 5:27-34
Published Date: 20 April 2016
High-throughput screening to enhance oncolytic virus immunotherapy
Allan KJ, Stojdl DF, Swift SL
Oncolytic Virotherapy 2016, 5:15-25
Published Date: 5 April 2016
Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances
Simpson GR, Relph K, Harrington K, Melcher A, Pandha H
Oncolytic Virotherapy 2016, 5:1-13
Published Date: 6 January 2016
Oncolytic virotherapy using herpes simplex virus: how far have we come?
Sokolowski NAS, Rizos H, Diefenbach RJ
Oncolytic Virotherapy 2015, 4:207-219
Published Date: 25 November 2015
Ultrasound-mediated oncolytic virus delivery and uptake for increased therapeutic efficacy: state of art
Nande R, Howard CM, Claudio PP
Oncolytic Virotherapy 2015, 4:193-205
Published Date: 25 November 2015
Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy
Nakashima H, Nguyen T, Chiocca EA
Oncolytic Virotherapy 2015, 4:183-191
Published Date: 20 November 2015
Targeting tumor vasculature through oncolytic virotherapy: recent advances
Toro Bejarano M, Merchan JR
Oncolytic Virotherapy 2015, 4:169-181
Published Date: 11 November 2015
Mechanistic insights into the oncolytic activity of vesicular stomatitis virus in cancer immunotherapy
Simovic B, Walsh SR, Wan YH
Oncolytic Virotherapy 2015, 4:157-167
Published Date: 15 October 2015
Patient-derived mesenchymal stem cells as delivery vehicles for oncolytic virotherapy: novel state-of-the-art technology
Ramírez M, García-Castro J, Melen GJ, González-Murillo A, Franco-Luzón L
Oncolytic Virotherapy 2015, 4:149-155
Published Date: 14 October 2015
Oncolytic Sendai virus-based virotherapy for cancer: recent advances
Saga K, Kaneda Y
Oncolytic Virotherapy 2015, 4:141-147
Published Date: 1 October 2015
Oncolytic virotherapy for human malignant mesothelioma: recent advances
Boisgerault N, Achard C, Delaunay T, Cellerin L, Tangy F, Grégoire M, Fonteneau JF
Oncolytic Virotherapy 2015, 4:133-140
Published Date: 10 September 2015
Characterization of an oncolytic adenovirus vector constructed to target the cMet receptor
Sakr HI, Coleman DT, Cardelli JA, Mathis JM
Oncolytic Virotherapy 2015, 4:119-132
Published Date: 4 September 2015
Advances in the design and development of oncolytic measles viruses
Hutzen B, Raffel C, Studebaker AW
Oncolytic Virotherapy 2015, 4:109-118
Published Date: 27 August 2015
On the potential of oncolytic virotherapy for the treatment of canine cancers
MacNeill AL
Oncolytic Virotherapy 2015, 4:95-107
Published Date: 26 August 2015
Oncolytic virotherapy for head and neck cancer: current research and future developments
Malhotra A, Sendilnathan A, Old MO, Wise-Draper TM
Oncolytic Virotherapy 2015, 4:83-93
Published Date: 20 July 2015
Novel therapeutic strategies in human malignancy: combining immunotherapy and oncolytic virotherapy
Sampath P, Thorne SH
Oncolytic Virotherapy 2015, 4:75-82
Published Date: 18 June 2015
Promising oncolytic agents for metastatic breast cancer treatment
Cody JJ, Hurst DR
Oncolytic Virotherapy 2015, 4:63-73
Published Date: 3 June 2015